GE’s Latin American CEO, 21 others, arrested in Brazil for fraud

Rio de Janeiro: Brazilian police arrested General Electric’s Latin America CEO Daurio Speranzini Junior on Wednesday as part of a probe into suspected fraud and corruption by multinational companies in the Rio de Janeiro state health system.

Speranzini, the former head of Philips Medical Systems in Brazil, was among 22 people arrested, including Frederik Knudsen, an executive at the Dutch company.

Police raided 44 sites, including the Brazilian headquarters of Philips and Johnson & Johnson, but not the offices of GE, the Rio prosecutors’ office said in a statement.

Code-named “Operation Resonance,” the probe was launched with the goal of dismantling a “suppliers’ cartel” accused of committing fraud to secure public health service contracts in Rio between 1996 and 2017.

The cartel, made up of at least 33 companies and led by Brazilian medical instrument distributors Oscar Iskin, was nicknamed the “international auctions club.”

“Top executives from multinational medical equipment manufacturers arranged among themselves who would win contracts by paying a 13 percent commission on those contracts to Iskin,” said the public prosecutor.

Iskin executives would then “serve as a link between public health authorities and the cartel’s companies” to steer contracts away from “competitors who weren’t part of the cartel.”

General Electric issued a statement asserting that the accusations against Speranzini referred to “a period when he was leading another company.”

Speranzini only became GE’s Latin America chief executive in January, having previously held the position of regional health department president from 2014 to 2017.

He was the Philips Medical Systems chief for Brazil from 2004 to 2010.

Philips said it was “cooperating with the authorities to shed light on the accusations that are several years old,” according to news website G1.

Johnson & Johnson Medical Devices Brazil told AFP it “rigorously follows the laws” of the country and is collaborating with the investigation.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

    Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

    Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

    Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

    India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

    India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Top 30 pharma companies post 12% revenue growth in first nine months

    Top 30 pharma companies post 12% revenue growth in first nine months

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory